- Producer of consistent, standardized medicinal cannabis
- Menu of cannabis strains with varying CBD:THC ratios
- ABcann’s CBD-Med is one of Canada’s highest-CBD products
In an interview with Cantech Letter (http://nnw.fm/IOcj0), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis for pain relief or other medical purposes, this was causing a great deal of concern.
Inconsistency in product quality makes the determination of optimal dosage levels impossible to achieve. As a result, “to deliver consistent, standardized medicinal cannabis that the public and patients can consistently rely on” became one of ABcann’s founding principles. That principle continues to guide the company to this day. The Canadian-licensed producer recently announced the release of one of Canada’s highest legal CBD:THC ratio cannabis products. This new product expands the range of therapies now available to patients and so increases the efficacy of current treatment regimens in the promising new field of cannabinoid therapies.
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer